The discovery of therapeutic antibodies that block the inhibitory molecules CTLA-4, PD-1, and PD-L1, consequently releasing the “breaks” on these checkpoints, stimulate T cells, unleashing an immune response against cancer cells [5, 6]. This evidence concerns the gene CD274 and cancer.